Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics

Until recently, Ebola virus (EBOV) was a rarely encountered human pathogen that caused disease among small populations with extraordinarily high lethality. At the end of 2013, EBOV initiated an unprecedented disease outbreak in West Africa that is still ongoing and has already caused thousands of de...

Full description

Bibliographic Details
Main Authors: Kugelman, Jeffrey R., Sanchez-Lockhart, Mariano, Andersen, Kristian G., Gire, Stephen, Park, Daniel J., Lin, Aaron E., Wohl, Shirlee, Sabeti, Pardis C., Kuhn, Jens H., Palacios, Gustavo F., Sealfon, Rachel Sima
Other Authors: Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
Format: Article
Language:en_US
Published: American Society for Microbiology 2015
Online Access:http://hdl.handle.net/1721.1/94325
_version_ 1826214741687664640
author Kugelman, Jeffrey R.
Sanchez-Lockhart, Mariano
Andersen, Kristian G.
Gire, Stephen
Park, Daniel J.
Lin, Aaron E.
Wohl, Shirlee
Sabeti, Pardis C.
Kuhn, Jens H.
Palacios, Gustavo F.
Sealfon, Rachel Sima
author2 Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
author_facet Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
Kugelman, Jeffrey R.
Sanchez-Lockhart, Mariano
Andersen, Kristian G.
Gire, Stephen
Park, Daniel J.
Lin, Aaron E.
Wohl, Shirlee
Sabeti, Pardis C.
Kuhn, Jens H.
Palacios, Gustavo F.
Sealfon, Rachel Sima
author_sort Kugelman, Jeffrey R.
collection MIT
description Until recently, Ebola virus (EBOV) was a rarely encountered human pathogen that caused disease among small populations with extraordinarily high lethality. At the end of 2013, EBOV initiated an unprecedented disease outbreak in West Africa that is still ongoing and has already caused thousands of deaths. Recent studies revealed the genomic changes this particular EBOV variant undergoes over time during human-to-human transmission. Here we highlight the genomic changes that might negatively impact the efficacy of currently available EBOV sequence-based candidate therapeutics, such as small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and antibodies. Ten of the observed mutations modify the sequence of the binding sites of monoclonal antibody (MAb) 13F6, MAb 1H3, MAb 6D8, MAb 13C6, and siRNA EK-1, VP24, and VP35 targets and might influence the binding efficacy of the sequence-based therapeutics, suggesting that their efficacy should be reevaluated against the currently circulating strain.
first_indexed 2024-09-23T16:10:25Z
format Article
id mit-1721.1/94325
institution Massachusetts Institute of Technology
language en_US
last_indexed 2024-09-23T16:10:25Z
publishDate 2015
publisher American Society for Microbiology
record_format dspace
spelling mit-1721.1/943252022-10-02T06:50:18Z Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics Kugelman, Jeffrey R. Sanchez-Lockhart, Mariano Andersen, Kristian G. Gire, Stephen Park, Daniel J. Lin, Aaron E. Wohl, Shirlee Sabeti, Pardis C. Kuhn, Jens H. Palacios, Gustavo F. Sealfon, Rachel Sima Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science Sealfon, Rachel Sima Until recently, Ebola virus (EBOV) was a rarely encountered human pathogen that caused disease among small populations with extraordinarily high lethality. At the end of 2013, EBOV initiated an unprecedented disease outbreak in West Africa that is still ongoing and has already caused thousands of deaths. Recent studies revealed the genomic changes this particular EBOV variant undergoes over time during human-to-human transmission. Here we highlight the genomic changes that might negatively impact the efficacy of currently available EBOV sequence-based candidate therapeutics, such as small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and antibodies. Ten of the observed mutations modify the sequence of the binding sites of monoclonal antibody (MAb) 13F6, MAb 1H3, MAb 6D8, MAb 13C6, and siRNA EK-1, VP24, and VP35 targets and might influence the binding efficacy of the sequence-based therapeutics, suggesting that their efficacy should be reevaluated against the currently circulating strain. United States. Defense Threat Reduction Agency National Science Foundation (U.S.). Graduate Research Fellowship Program (Grant DGE 1144152) 2015-02-11T16:09:18Z 2015-02-11T16:09:18Z 2015-01 2014-10 Article http://purl.org/eprint/type/JournalArticle 2150-7511 http://hdl.handle.net/1721.1/94325 Kugelman, Jeffrey R., Mariano Sanchez-Lockhart, Kristian G. Andersen, Stephen Gire, Daniel J. Park, Rachel Sealfon, Aaron E. Lin, et al. “Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics.” mBio 6, no. 1 (January 20, 2015): e02227–14. en_US http://dx.doi.org/10.1128/mBio.02227-14 mBio Creative Commons Attribution http://creativecommons.org/licenses/by-nc-sa/3.0/ application/pdf American Society for Microbiology American Society for Microbiology
spellingShingle Kugelman, Jeffrey R.
Sanchez-Lockhart, Mariano
Andersen, Kristian G.
Gire, Stephen
Park, Daniel J.
Lin, Aaron E.
Wohl, Shirlee
Sabeti, Pardis C.
Kuhn, Jens H.
Palacios, Gustavo F.
Sealfon, Rachel Sima
Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics
title Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics
title_full Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics
title_fullStr Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics
title_full_unstemmed Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics
title_short Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics
title_sort evaluation of the potential impact of ebola virus genomic drift on the efficacy of sequence based candidate therapeutics
url http://hdl.handle.net/1721.1/94325
work_keys_str_mv AT kugelmanjeffreyr evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT sanchezlockhartmariano evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT andersenkristiang evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT girestephen evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT parkdanielj evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT linaarone evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT wohlshirlee evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT sabetipardisc evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT kuhnjensh evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT palaciosgustavof evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics
AT sealfonrachelsima evaluationofthepotentialimpactofebolavirusgenomicdriftontheefficacyofsequencebasedcandidatetherapeutics